Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1642 1648 1671 1675
This examiner grants 64% of resolved cases
Nianxiang Zou is an examiner in Tech Center 1600, operating within Art Unit 1600. With a substantial history of 778 resolved cases, this examiner has a well-defined statistical profile. The data indicates an allowance rate of 64.1 percent, which serves as a primary benchmark for applicants in this docket.
The interview lift is 24.8 percent, suggesting that direct communication with the examiner is a productive strategy. This lift indicates that cases involving an interview are significantly more likely to result in an allowance than those that do not. The median days to allowance is 993, providing a clear expectation for the total duration of the patent prosecution process.
Practitioners should consider the 64.1 percent allowance rate when evaluating the strength of their claims. The 993 days to allowance is a key figure for managing client expectations regarding timing. Given the 24.8 percent interview lift, scheduling a formal discussion with the examiner early in the process may help in resolving technical issues and moving the application toward a grant more effectively.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17800687 | Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18847937 | METHODS AND COMPOSITIONS FOR PURIFYING ADENO ASSOCIATED VIRUS PARTICLES | Non-Final OA | MERCK PATENT GMBH |
| 18344952 | METHODS FOR DETERMINING SARS-COV-2 ANTIGEN AND ANTI-SARS-COV-2 ANTIBODY IN A SAMPLE | Final Rejection | Abbott Laboratories |
| 18560515 | Coronavirus Constructs and Vaccines | Non-Final OA | The Regents of the University of California |
| 17817382 | HPV VACCINE | Final Rejection | Merck Sharp & Dohme LLC |
| 17862240 | Methods for Viral Particle Characterization Using Two-Dimensional Liquid Chromatography-Mass Spectrometry | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18520057 | E1E2 HCV VACCINES AND METHODS OF USE | Final Rejection | The Governors of the University of Alberta |
| 18283435 | METHOD TO ASSESS POTENCY OF VIRAL VECTOR PARTICLES | Non-Final OA | Juno Therapeutics, Inc. |
| 18017073 | GDF-15 FOR PREDICTING THE DISEASE SEVERITY OF A PATIENT WITH COVID-19 | Final Rejection | Roche Diagnostics Operations, Inc. |
| 18833823 | CORONAVIRUS ANTIGEN VARIANTS | Non-Final OA | PFIZER INC. |
| 18689656 | Universal Influenza Vaccine and Methods of Use | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18835922 | ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME | Non-Final OA | Takeda Vaccines, Inc. |
| 18750485 | RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18704211 | SINGLE DOMAIN ANTIBODIES TARGETING THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN | Non-Final OA | The U.S.A., as represented by the Secretary, Department of Health and Human Services |
| 18503487 | Vaccines For Human Papilloma Virus And Methods For Using The Same | Non-Final OA | Inovio Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy